Active substance
Results for the substance vedolizumab
3 results
About this active substance
Vedolizumab is a medication used for the treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis in patients who have not responded adequately to other therapies. It is a humanized monoclonal antibody that targets the α4β7 integrin, a protein involved in the migration of lymphocytes to the gastrointestinal tract. By blocking this protein, vedolizumab reduces intestinal inflammation without affecting the systemic immune system.
The medication is administered intravenously, usually at regular intervals, depending on the treatment regimen recommended by the physician. Treatment requires periodic monitoring to assess efficacy and detect potential adverse reactions.
Common side effects include headaches, nausea, fever, upper respiratory tract infections, and fatigue. In rare cases, severe adverse reactions such as hypersensitivity reactions or serious infections may occur.
Vedolizumab represents an important therapeutic option for patients with Crohn's disease or ulcerative colitis, helping to reduce symptoms and improve their quality of life.
The medication is administered intravenously, usually at regular intervals, depending on the treatment regimen recommended by the physician. Treatment requires periodic monitoring to assess efficacy and detect potential adverse reactions.
Common side effects include headaches, nausea, fever, upper respiratory tract infections, and fatigue. In rare cases, severe adverse reactions such as hypersensitivity reactions or serious infections may occur.
Vedolizumab represents an important therapeutic option for patients with Crohn's disease or ulcerative colitis, helping to reduce symptoms and improve their quality of life.
-
-
ENTYVIO 108mg solution for injection in pre-filled pen TAKEDA ORIGINAL MEDICINE
-
ENTYVIO 108mg solution for injection in pre-filled syringe TAKEDA ORIGINAL MEDICINE